image
Healthcare - Drug Manufacturers - General - NYSE - DK
$ 67.55
-4.09 %
$ 302 B
Market Cap
19.33
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NVO stock under the worst case scenario is HIDDEN Compared to the current market price of 67.5 USD, Novo Nordisk A/S is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NVO stock under the base case scenario is HIDDEN Compared to the current market price of 67.5 USD, Novo Nordisk A/S is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NVO stock under the best case scenario is HIDDEN Compared to the current market price of 67.5 USD, Novo Nordisk A/S is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVO

image
$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.0$70.0$70.0$60.0$60.0$50.0$50.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
290 B REVENUE
25.03%
128 B OPERATING INCOME
25.12%
101 B NET INCOME
20.68%
121 B OPERATING CASH FLOW
11.07%
-129 B INVESTING CASH FLOW
-193.66%
8.74 B FINANCING CASH FLOW
113.83%
85.7 B REVENUE
20.15%
36.7 B OPERATING INCOME
8.30%
28.2 B NET INCOME
3.40%
12.3 B OPERATING CASH FLOW
-71.95%
-91.2 B INVESTING CASH FLOW
-336.36%
36.8 B FINANCING CASH FLOW
300.18%
Balance Sheet Novo Nordisk A/S
image
Current Assets 161 B
Cash & Short-Term Investments 26.3 B
Receivables 87.4 B
Other Current Assets 47.2 B
Non-Current Assets 305 B
Long-Term Investments 2.68 B
PP&E 162 B
Other Non-Current Assets 140 B
5.65 %18.77 %10.13 %34.88 %30.00 %Total Assets$465.8b
Current Liabilities 218 B
Accounts Payable 28.8 B
Short-Term Debt 13.1 B
Other Current Liabilities 176 B
Non-Current Liabilities 105 B
Long-Term Debt 89.7 B
Other Non-Current Liabilities 15.1 B
8.95 %4.07 %54.47 %27.82 %4.69 %Total Liabilities$322.3b
EFFICIENCY
Earnings Waterfall Novo Nordisk A/S
image
Revenue 290 B
Cost Of Revenue 44.5 B
Gross Profit 246 B
Operating Expenses 118 B
Operating Income 128 B
Other Expenses 27.4 B
Net Income 101 B
300b300b250b250b200b200b150b150b100b100b50b50b00290b(45b)246b(118b)128b(27b)101bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
84.67% GROSS MARGIN
84.67%
44.19% OPERATING MARGIN
44.19%
34.78% NET MARGIN
34.78%
70.38% ROE
70.38%
21.68% ROA
21.68%
38.99% ROIC
38.99%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Novo Nordisk A/S
image
80b80b70b70b60b60b50b50b40b40b30b30b20b20b10b10b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 101 B
Depreciation & Amortization 8.54 B
Capital Expenditures -51.3 B
Stock-Based Compensation 2.29 B
Change in Working Capital -12 B
Others 3.05 B
Free Cash Flow 69.7 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Novo Nordisk A/S
image
Wall Street analysts predict an average 1-year price target for NVO of $158 , with forecasts ranging from a low of $156 to a high of $160 .
NVO Lowest Price Target Wall Street Target
156 USD 130.94%
NVO Average Price Target Wall Street Target
158 USD 134.49%
NVO Highest Price Target Wall Street Target
160 USD 136.86%
Price
Max Price Target
Min Price Target
Average Price Target
160160140140120120100100808060604040Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
1.1 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
1.200001.200001.000001.000000.800000.800000.600000.600000.400000.400000.200000.200000.000000.000000.380.4820.33150.3350.39450.782610.47450.5180.59450.929851.099210.22350.600.2370.720.23350.570.22450.560.2590.650.27851.060.2920.770.4420.960.512641.110.931.102015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Novo Nordisk A/S
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
GLP-1 competition heats up: Novo Nordisk CEO talks Wegovy, CVS deal, earnings Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). youtube.com - 1 week ago
Trump's trade war and inflation, Novo Nordisk CEO talks earnings Catalyst anchor Madison Mills breaks down the market moves for May 7, 2025. First, all eyes are on the Federal Reserve. youtube.com - 1 week ago
Novo Nordisk A/S (NVO) Q1 2025 Earnings Call Transcript Novo Nordisk A/S (NVO) Q1 2025 Results Conference Call May 7, 2025 7:00 AM ET Company Participants Jacob Rode - Head of Investor Relations Lars Jorgensen - President and Chief Executive Officer David Moore - Executive Vice President, U.S. Operations and Global Business Development Mike Doustdar - Executive VP of International Operations Martin Holst Lange - Executive Vice President and Head of Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Call Participants Richard Vosser - JPMorgan Chase & Co. James Quigley - Goldman Sachs Peter Verdault - BNP Paribas Martin Parkhoi - SEB Michael Nedelcovych - TD Cowen Sachin Jain - Bank of America Merrill Lynch Jo Walton - UBS Operator Good day, and thank you for standing by. Welcome to the Q1 2025 Novo Nordisk A/S Earnings Conference Call. seekingalpha.com - 1 week ago
Why Novo Nordisk Stock Popped After Earnings GLP-1 drugmaker Novo Nordisk's (NVO 2.01%) stock jumped at the open and remains up 3.2% as of 10:20 a.m. ET after the company reported earnings this morning. fool.com - 1 week ago
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy. zacks.com - 1 week ago
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn, with diluted EPS up 15% year-on-year. ~65% of revenues were driven by semaglutide, or Wegovy (obesity)/Ozempic (diabetes). This is truly a miraculous drug, and as compounded versions of semaglutide cease to be manufactured, performance will improve in 2H25. seekingalpha.com - 1 week ago
SMCI Miss "Across the Board," NVO Wegovy Sales Up 85%, ANET Down on Beat Diane King Hall discusses the biggest earnings movers this morning, including Novo Nordisk (NVO), which saw a 85% year-over-year increase in Wegovy sales but still trimmed guidance. Supermicro (SMCI) "missed across the board" in its earnings and trimmed guidance. youtube.com - 1 week ago
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant. cnbc.com - 1 week ago
Novo Nordisk investors relieved after expected guidance cut Novo Nordisk (NYSE:NVO) first-quarter results offered few surprises, but they may just have delivered the market something it needed more: relief. That collective anxiety release was reflected in the share price, which rose 4%. proactiveinvestors.co.uk - 1 week ago
Novo Blames Compounders As It Cuts 2025 Forecast. Shares Jump. Novo Nordisk stock jumped early Wednesday despite cutting its 2025 outlook due what Novo says is illegal compounding of GLP-1 medicines. investors.com - 1 week ago
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise, defying the 55% stock drop. Novo Nordisk's profitability and growth in emerging markets, coupled with a forward P/E ratio of 16.35x, make it an undervalued investment opportunity. Market concerns over minor market share losses are overblown; NVO remains the leader in a rapidly growing obesity and diabetes market. seekingalpha.com - 1 week ago
Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut U.S.-listed shares of Novo Nordisk (NVO) are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook. investopedia.com - 1 week ago
8. Profile Summary

Novo Nordisk A/S NVO

image
COUNTRY DK
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 302 B
Dividend Yield 0.00%
Description Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Contact Novo Alle 1, Bagsvaerd, 2880 https://www.novonordisk.com
IPO Date April 30, 1981
Employees 76302
Officers Mr. Henrik Ehlers Wulff Executive Vice President of CMC & Product Supply and Member of the Management Board Mr. David S. Moore Executive Vice President of US Operations & Member of Management Board Mr. Maziar Mike Doustdar Executive Vice President of International Operations & Member of the Management Board Ms. Tania Sabroe EVice President of People, Organisation and Communication & Member of Management Board Mr. Lars Fruergaard Jorgensen President, Chief Executive Officer & Member of Management Board Mr. Karsten Munk Knudsen Executive Vice President, Chief Financial Officer & Member of the Management Board Dr. Martin Holst Lange Executive Vice President of Development & Member of the Management Board Dr. Marcus Schindler Ph.D. EVice President of Research & Early Development, Chief Scientific Officer & Member of the Management Board Ms. Thilde Hummel Bogebjerg Executive Vice President of Quality, IT & Environmental Affairs and Member of Management Board Mr. Ludovic Helfgott Executive Vice President of Product & Portfolio Strategy and Member of Management Board